Omeros (OMER) Stock Surges After Hours on Dec. 24, 2025 After FDA Approves Yartemlea — What to Know Before the Next Market Open
Omeros shares jumped 75% to $15.36 in after-hours trading Wednesday after the FDA approved its first commercial product, YARTEMLEA, for a rare post-transplant complication. The stock saw heavy volume and a wide range, with multiple trading halts reported. U.S. markets closed early for Christmas Eve and will reopen Friday. The FDA had previously rejected the drug in 2021.